Analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will report ($0.46) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Heron Therapeutics’ earnings. The lowest EPS estimate is ($0.64) and the highest is ($0.28). Heron Therapeutics reported earnings of ($0.81) per share in the same quarter last year, which suggests a positive year over year growth rate of 43.2%. The firm is expected to issue its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($2.01) to ($0.98). For the next fiscal year, analysts expect that the firm will report earnings of $0.75 per share, with EPS estimates ranging from $0.07 to $2.42. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.17). The business had revenue of $28.84 million for the quarter, compared to analyst estimates of $28.05 million. Heron Therapeutics had a negative net margin of 230.84% and a negative return on equity of 54.98%.
Shares of NASDAQ:HRTX traded down $0.86 during midday trading on Friday, hitting $24.09. 661,824 shares of the company’s stock traded hands, compared to its average volume of 891,577. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -9.87 and a beta of 1.57. Heron Therapeutics has a twelve month low of $21.25 and a twelve month high of $42.90.
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Heron Therapeutics by 36.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after buying an additional 1,661,318 shares during the period. Vanguard Group Inc increased its position in shares of Heron Therapeutics by 36.7% in the 3rd quarter. Vanguard Group Inc now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares during the last quarter. BlackRock Inc. increased its position in shares of Heron Therapeutics by 2.8% in the 4th quarter. BlackRock Inc. now owns 4,913,006 shares of the biotechnology company’s stock worth $127,443,000 after purchasing an additional 132,207 shares during the last quarter. FIL Ltd increased its position in shares of Heron Therapeutics by 3.5% in the 3rd quarter. FIL Ltd now owns 3,063,383 shares of the biotechnology company’s stock worth $96,956,000 after purchasing an additional 103,224 shares during the last quarter. Finally, Rubric Capital Management LP increased its position in shares of Heron Therapeutics by 71.8% in the 3rd quarter. Rubric Capital Management LP now owns 1,958,850 shares of the biotechnology company’s stock worth $61,998,000 after purchasing an additional 818,603 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Story: How do buyers and sellers choose a strike price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.